Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE.
BROMPHENIRAMINE MALEATE vs PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Pseudoephedrine is a sympathomimetic amine that acts as an indirect agonist at alpha- and beta-adrenergic receptors, causing vasoconstriction in the nasal mucosa and bronchodilation. Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms such as sneezing, rhinorrhea, and pruritus.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
1 tablet (pseudoephedrine HCl 60 mg + triprolidine HCl 2.5 mg) orally every 4-6 hours, not to exceed 4 doses in 24 hours.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Pseudoephedrine: 5-8 hours (pH-dependent; alkaline urine increases half-life); Triprolidine: approximately 2-4 hours. Combined product: pseudoephedrine half-life is clinically relevant for dosing frequency.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Pseudoephedrine: ~70-90% renal as unchanged drug, minor hepatic metabolism (N-demethylation); Triprolidine: extensively hepatic metabolized, renal elimination of metabolites and unchanged drug (<5% unchanged), total excretion primarily renal and biliary.
Category C
Category A/B
Antihistamine
Antihistamine